Solésence (SLSN) Q3 2026 earnings review
Solésence profit hits a record, and factory debt drops 42%
Solésence, a maker of mineral-based sun-care and beauty products for consumer brands, turned its factory overhaul into record quarterly profit and a much lighter debt load. Third-quarter revenue rose 38% from a year ago to $20.2 million, and gross margin reached 39% as production costs fell. Chief executive Kevin Cureton said the main phase of its factory efficiency programme is now complete, though the release gave no fourth-quarter forecast and by our math the prior second-half plan leaves $14.8 million for the fourth quarter.
| Revenue | $20.2M +38% from a year ago (+32% from Q2) |
|---|---|
| Gross margin | 39.3% 23.8% a year ago (31.0% in Q2) |
| Related-party debt | $8.3M down 42% from $14.3M in Q2 |
| 2027 outlook | Qualitative prior $35M H2 plan leaves $14.8M for Q4 |
⚖️ Verdict: 🟢 Bullish
The story got better because the margin expansion is now visible on restated numbers and cash flow paid down 42% of the company's related-party debt in a single quarter. Filing the amended annual report on November 10 also eased the accounting overhang from last quarter's ten-period inventory restatement. One caution: the press release dropped the order-book metric and gave no update ऑन whether one brand partner still accounts for over half of sales.
The question now is whether a 39% gross margin and $20 million in quarterly sales are a new baseline or a seasonal spike from one major customer's reorders. If new product lines and a broader customer list drove the jump, fourth-quarter sales will beat the $14.8 million implied remainder; if it was a single customer's timing, revenue and factory margins will drop back in the fourth quarter. The third-quarter 10-Q customer concentration footnote and fourth-quarter results will settle it.
🐂 Bull Case
Factory Overhaul Lifted Gross Margin to 39.3%
Solésence makes mineral-based sun-care and beauty products for consumer brands. Over the past year, manufacturing waste and an inventory accounting restatement raised doubts about whether its factory overhaul was working. Chief executive Kevin Cureton said the beauty manufacturer has now finished the main investment phase of its "operational excellence" programme, which reorganised factory shifts and automated production lines.
- Gross margin: 39.3%, up 15.5 percentage points from a year ago and up from 31.0% last quarter
- Cost of making the products: 60.7% of revenue, down from 76.2% a year ago
- Operating margin: 20.0%, compared with a negative 4.6% margin a year ago
Earlier quarters showed almost no margin gain once the accounting restatement was applied, so this jump is the first clean proof that lower unit labor costs and higher factory volume are lifting profits. By our math, nine-month gross margin is now 32.5% versus a restated 27.3% last year. That puts the full-year 30% margin floor well within reach unless fourth-quarter margin falls below 22%.
What to watch: fourth-quarter gross margin on seasonally lower volume. Holding above the 30% floor when quarterly sales drop back toward $15 million would show the cost savings do not depend solely on peak third-quarter shipments.
Cash Generation Cut Related-Party Debt by 42%
Solésence funds its working capital through credit lines from companies tied to its majority shareholder, and those loans come due in April 2027. Entering the quarter, the skin-care group held just $1.0 million in cash against $14.3 million of related-party debt, and it had needed a lender waiver after the inventory restatement shrank its borrowing base.
In the third quarter, the Illinois manufacturer used its record $3.7 million profit and lower inventory to pay down $6.0 million of those loans. By our math, total related-party debt fell 41.7% in three months to $8.3 million: the receivables credit line dropped from $3.8 million to $1.0 million, and the inventory line fell from $9.5 million to $6.3 million. Net inventory declined 10.5% from June to $11.6 million.
What to watch: the debt footnote in the third-quarter filing and fourth-quarter loan balances. Paying down nearly half the balance lowers refinancing risk, but the remaining $8.3 million still matures in April 2027 and needs a formal extension.
Amended Annual Report Filed Ahead of Earnings
Last quarter, Solésence uncovered an error in how it assigned factory labor and overhead to inventory across ten reporting periods. Because of that error, the group filed its second-quarter report without an independent auditor review and promised amended historical filings. The third-quarter release notes that the restatement of its annual report was completed, "as amended by Form 10-K/A filed on November 10, 2026", and prints updated 2025 comparison numbers.
The restated figures raised third-quarter 2025 gross profit by $104 thousand to $3.5 million, lifting the prior-year gross margin to 23.8% from the originally reported 23.1%. Filing the amended annual report clears a major compliance hurdle, though a small date typo on the new balance sheet stub shows administrative controls still need care.
What to watch: the third-quarter Form 10-Q headings. Investors need to confirm that the independent auditor has resumed reviewing the quarterly statements and that all amended quarterly reports are on file.
Positives this quarter didn't test
Cureton pointed to "continued innovation in novel formulations and expanding global presence", but the earnings release gave no numbers on two standing growth initiatives.
- New product categories: Chromalüm, WHSPR and a July scalp-care launch got no revenue breakdown; the quarterly filing or conference call will show whether orders are building beyond facial sun care.
- Turnkey supply and international expansion: planned to begin in early 2027, with no named overseas brand partners in the release; first-quarter 2027 updates will test this expansion.
🐻 Bear Case
No Forward Numbers or Order Book in the Release
Cureton said the factory upgrade positions the sun-care maker "to meet robust demand from our brand partners today while seamlessly scaling for tomorrow", and finance chief Laura Riffner said 2026 improvements "provide a strong foundation as we look ahead to 2027". Despite that upbeat tone, the press release gave no dollar target for the fourth quarter or for 2027.
The release also left out shipped and on-hand orders, a forward backlog figure Riffner cited at $64.9 million on last quarter's call. Without an updated order book or a raised second-half plan, the standing $35 million second-half target leaves just $14.8 million of revenue for the fourth quarter by our math. That would mark a 26.4% drop from the third quarter's $20.2 million.
What to watch: whether Riffner provides an updated 2026 and 2027 order book on the conference call. Silence or a sequential fourth-quarter drop toward $15 million would show that third-quarter shipments mostly cleared existing backlog rather than starting a new $20 million quarterly run rate.
Risks this quarter didn't answer
The earnings release only includes condensed statements and reiterates standard risk warnings about "dependence on a limited number of key customers", leaving four standing risks unaddressed until the full quarterly filing.
- Single-customer reliance: one brand partner accounted for 58% of second-quarter revenue and 72% of gross receivables; Note 8 of the upcoming 10-Q will show whether the third-quarter jump came from that same customer or a broader base.
- April 2027 debt maturity: $8.3 million of related-party credit lines still mature in five months; Note 6 of the 10-Q will show if the majority shareholder's affiliates have extended the deadline.
- Ingredient volumes and BASF contract: personal-care ingredient sales fell 60% last quarter near an equipment-sale trigger; Note 9 of the 10-Q will show if ingredient volumes stabilized.
- Non-mineral sunscreen competition: US regulatory approval of BEMT, a competing chemical sun filter, got no mention in the release; 2027 brand reorder rates will test whether mineral formulas lose share.
💲 Other KPIs
Customer deposits — cash brand partners pay upfront for future production runs — rose for a third straight quarter. The balance climbed from $0.93 million at year-end and $1.94 million in June to $2.15 million, up 79.4% from a year ago, supporting near-term factory schedules.
Uncollected customer bills rose 22.4% from $6.84 million at the end of 2025 as third-quarter shipments climbed. The allowance for unpaid bills ticked up slightly from $806 thousand at year-end to $858 thousand.
Overhead and sales spending fell 8.4% from $3.07 million a year ago, when the beauty supplier paid $400 thousand in executive severance and Nasdaq listing fees. It also dropped from $3.68 million in the second quarter, which carried a $938 thousand customer settlement charge.
🔮 Guidance
New. Riffner said the operational and financial gains made across 2026 "provide a strong foundation as we look ahead to 2027", without giving numerical revenue or margin targets. The press release also gave no update to last quarter's $35 million second-half 2026 revenue plan, which by our math leaves $14.8 million for the fourth quarter (+18.9% from a year ago, down 26.4% from Q3).
❓ Key Questions
Where do shipped and on-hand orders stand now?
Riffner reported $64.9 million of in-year orders in August, which backed the $35 million second-half plan. The press release omitted the figure, leaving investors unable to tell if fourth-quarter orders rose above the implied $14.8 million remainder.
How much of Q3 came from the top customer?
A single brand partner generated 58% of second-quarter sales and 72% of gross receivables. Investors need Note 8 of the quarterly filing to see whether the 38% third-quarter sales jump diversified the customer base or deepened that reliance.
Have related-party lenders extended the April 2027 deadline?
Solésence paid down $6.0 million of related-party credit lines this quarter, cutting the balance to $8.3 million. However, all $8.3 million still matures on April 30, 2027 against $1.3 million of cash.
Did the independent auditor review the Q3 statements?
The company filed its amended 2025 annual report on November 10, two days before earnings, after issuing unreviewed second-quarter statements. The upcoming 10-Q will show whether the auditor review is complete and whether internal controls are remediated.